Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| As a result of this successful collaboration with our CMO that is no longer the case, and the availability of fully GMP material from a scaled up manufacturing process for the active ingredient represents yet another positive step forward in the development of our product |
| We firmly believe that this global commercial network is unprecedented for a company our size and represents highly differentiated and perhaps somewhat underappreciated advantage for Quoin |
| We are very excited about these new developments in our clinical programs and as discussed, we believe these protocol amendments may ultimately result in a faster approval for QRX003 in Netherton Syndrome and with a more compelling data set |
| We are extremely pleased with these results as pruritus can be extremely distressing and debilitating for Netherton patients |
| Again, based on the body of clinical evidence generated to date, in conjunction with the very clean safety profile observed so far, we believe that twice daily dosing of the product has the potential to deliver a more robust clinical evidence of efficacy across all measured endpoints |
| So these developments are positive overall |
| I can just say, look, we have agreed financial terms that we believe are favorable to Quoin, so we’re excited about that |
| We believe we have a great asset |
| The potential incremental revenue generating opportunity that this global commercial partnership network represents for our company, all of which will effectively fall to the bottom line could ultimately be highly significant for the company and have a materially positive impact on our future profitability |
| Taken together, the body of clinical evidence generated state from both an efficacy and a safety perspective has led to a number of exciting developments for our two ongoing clinical studies, enabling us to move into an optimization phase, which we believe may ultimately result in an even more robust and diverse data set and potentially to a faster approval for the product |
| Finally, and also importantly, there were no significant adverse events reported throughout the study and the overall safety profile of QRX003 to date is extremely favorable and highly suggestive of a potentially safe treatment for this disease |
| Importantly also, all six subjects expressed satisfaction with QRX003 across a number of assessed metrics, leading to a positive overall experience with the product |
| As we continue to make significant progress on the clinical front ourselves, we and our now nine global marketing partners are more excited than ever by the potential commercial opportunity that of what could be the first regulatory approved product for this horrendous disease |
| So the clinical data, you’ve done a very strong job in securing distribution |
| During this past quarter, we continue to make significant progress across multiple fronts culminating in the release of additional positive clinical data for QRX003 from our ongoing open-label clinical trial in Netherton Syndrome after the quarter ended on October 24 |
| We are entering a very exciting period for Quoin |
| I’m pleased to announce today that our contract manufacturer, our CMO for the active ingredient in QRX003 has successfully developed and scaled up a new and fully GMP manufacturing process for the drug substance |
| We believe that these planned protocol amendments will result in an even more robust clinical data set and potentially lead to a faster and possibly wider initial regulatory approval for the product |
| It does affect the pace at which data will be released, but overall, we believe we remain on track and possibly able to speed up the approval of the product |
| Nice to meet you again |
| As you know, QRX003 is an easily applied and user friendly topical lotion, which makes it attractive to use for patients and caregivers |
| Based on the positive clinical data reported recently, we are making a number of protocol adjustments to our ongoing clinical studies, which we believe may lead to a more rapid approval with a broader and more robust data set |
| As outlined in our press release on that date, the data was positive across several measured endpoints |
| While I’m not in a position to provide any specific details, I can tell you that all three assets are rare disease products that would strongly complement and enhance our current product portfolio |
| On October 24, we announced the release of positive clinical data from our single arm open-label study |
| and Europe will facilitate what will effectively amount to a global launch of the product once approved, and also lay the foundation for similar global launches of our pipeline products once they also receive regulatory approval |
| Following an extensive and broad-based process throughout this year, where we assessed well over 20 different opportunities during the past quarter, we successfully narrowed that list down to three specific products for which we ultimately reached agreement on all key financial terms |
| Unidentified Analyst That’s a pretty strong number |
| As discussed, given our strong balance sheet and potential access to additional capital, we have been acutely focused on expanding our product portfolio via acquisition, licensing or other means |
| In terms of price point, we haven’t drilldown to a point where I’m comfortable saying giving you an exact number, but the opportunity here, we believe is substantially in excess of $500 million in total and could be significantly higher |
| Statement |
|---|
| Our operating loss for the third quarter was $2.1 million compared to $2.3 million for the third quarter of 2022 |
| And like I said, it’s getting all your cash for $0.30 on a dollar makes very little sense |
| You guys are just so undervalued, it’s ridiculous |
| What is particularly noteworthy is that despite receiving long-term off label systemic therapy, all six subjects were experiencing significant pruritus at baseline and for five of those six, that pruritus had largely disappeared following treatment with QRX003 |
Please consider a small donation if you think this website provides you with relevant information